(±)-Salsolinol (hydrochloride) |
| Catalog No.GC13786 |
depolarize dopamineric neurons
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 79923-51-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(±)-Salsolinol targets depolarize dopamineric neurons.
Dopaminergic neurons produce dopamine, a neurotransmitter with various roles in neurological functions. Progressive loss of dopaminergic neurons is considered as the cause of many motor symptoms associated with Parkinson’s disease.
In vitro: A previous study found that (±)-salsolinol could activate the μ-opioid receptor by the classical G protein-adenylate cyclase pathway. The agonist action of (±)-salsolinol was blocked by the μ-opioid antagonist. The EC50 for the purified stereoisomers (R)- salsolinol and (S)-salsolinol were 6 × 10-4 M and 9 × 10-6 M, respectively. It was found that (±)-salsolinol did not promote the recruitment of β-arrestin. Molecular docking studies showed that the interaction of (R)- and (S)-salsolinol with the μ-opioid receptor was similar to that predicted for the agonist morphine [1].
In vivo: Male Wistar rats were subjected to continuous i.p. dosing of salsolinol at 200 mg/kg for 2 or 4 weeks with either high-fat or normal diet. Results showed that salsolinol could reduce total body mass significantly with no differences in total food intake. In addition, the epididymal fat pad weight over final body mass ratio was lower in salsolinol treated rats with high fat diet. Moreover, the perimeter, e area, as well as short and long axis of the fad pad adipocytes decreased in salsolinol treated animals significantly [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Berríos-Cárcamo P, Quintanilla ME, Herrera-Marschitz M, Vasiliou V, Zapata-Torres G, Rivera-Meza M. Racemic Salsolinol and its Enantiomers Act as Agonists of the μ-Opioid Receptor by Activating the Gi Protein-Adenylate Cyclase Pathway. Front Behav Neurosci. 2017 Jan 23;10:253. doi: 10.3389/fnbeh.2016.00253. eCollection 2016.
[2] Aleksandrovych V, Kurnik M, Biaas M, Bugajski A, Thor P, Gil K. The effect of peripheral chronic salsolinol administration on fat pad adipocytes morphological parameters. Folia Med Cracov. 2016;56(1):81-95.
| Cas No. | 79923-51-6 | SDF | |
| Chemical Name | 1,2,3,4-tetrahydro-1-methyl-6,7-isoquinolinediol, monohydrochloride | ||
| Canonical SMILES | CC1NCCC2=C1C=C(O)C(O)=C2.Cl | ||
| Formula | C10H13NO2 • HCl | M.Wt | 215.7 |
| Solubility | Soluble in ethanol;Soluble in DMSO;Soluble in Water | Storage | Store at 4°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.6361 mL | 23.1803 mL | 46.3607 mL |
| 5 mM | 0.9272 mL | 4.6361 mL | 9.2721 mL |
| 10 mM | 0.4636 mL | 2.318 mL | 4.6361 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *